GC Biopharma, a biotechnology pioneer in South Korea, is now preparing to take another major leap forward toward ensuring a healthier and happier future for all peoples worldwide. Challenge and innovation, care and compassion, transparency and integrity, and respect and dedication are the core principles that guide GC Biopharma on its journey toward achieving its next goal.
Pharmaceutical research is ridden with challenges and hardships. Knowing its importance to people struggling with disease, however, GC Biopharma has been ceaselessly pursuing its mission with single-mindedness toward becoming a global health industry leader. GC Biopharma is now ready to join the ranks of the global health industry, as an active member in research, development, and provision of a broad array of pharmaceutical products, medical devices, and healthcare services for better global prevention, diagnosis, and treatment of diseases of the body and mind.
GC Biopharma’s relentless drive to rise to meet new challenges with innovative solutions has made the company what it is today. Having always preferred to blaze new trails over following easy and simple paths, GC Biopharma intends to strengthen its reputation and brand through greater R&D efforts.
GC Biopharma has researched and developed innovative drugs for patients with rare diseases, and continues to undertake charity work for the excluded and marginalized. We are dedicated to restoring hope to patients over and beyond simply treating their illnesses.
GC Biopharma refuses to reach its goals by anything other than the right way. The company has grown with an unswerving conviction that there are right ways to do things, no matter how long and painstaking they may be. We honor and cherish the founding commitment to prioritize respect for life above profitmaking.
Respect for life is the first and foremost value guiding all GC Biopharma pursuits. We remain committed to maximizing benefits and value for all our clients, including patients, medical practitioners, shareholders, and investors.